Lv6
3140 积分 2024-08-20 加入
Hetero-bivalent agents targeting FAP and PSMA
11天前
已完结
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
24天前
已完结
Preclinical positron emission computed tomography of prolonged tumor growth after lutetium-177 prostate-specific membrane antigen treatment in xenograft model of human prostate cancer
24天前
已关闭
Biodistribution of 177Lu-DOTA-PSMA in Mice with Prostate Carcinoma 22Rv1
24天前
已完结
PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer
1个月前
已完结
Rethinking therapeutic strategies of dual-target drugs: An update on pharmacological small-molecule compounds in cancer
1个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
1个月前
已完结
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
3个月前
已完结
Single-molecule protein sequencing with nanopores
6个月前
已完结
Spatial multi-omics at subcellular resolution via high-throughput in situ pairwise sequencing
7个月前
已完结
皖公网安备34019202002308
